Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells

(2014) You Zhou et al.   BIOMEDICINE & PHARMACOTHERAPY

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

(2014) Katrina J. Falkenberg et al.   NATURE REVIEWS DRUG DISCOVERY

Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment

(2014) De-Si Pan et al.   MedChemComm

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

(2013) O. Odejide et al.   BLOOD

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

(2013) Vivien Mak et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

(2013) Yushi Yao et al.   PLoS One

Distribution of Lymphoid Neoplasms in China

(2012) Jian Sun et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells

(2012) Ke Gong et al.   BIOCHEMICAL JOURNAL

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

(2012) Mei Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

(2011) Zhi-Qiang Ning et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY